Bionexus Gene Lab Corp (BGLC) Stock Price & Analysis
Bionexus Gene Lab Corp (BGLC) fell 0.68% to USD 2.18 as of June 10, 2026 at 00:28 UTC, according to Nexqual real-time market data.
BGLC last closed at USD 2.19; the session ranged USD 2.15–2.2 on volume of 6,790 shares. Market capitalization is $5.26M, with a 52-week range of USD 1.92–15.6 (NCM). Source: Nexqual, June 10, 2026 at 00:28 UTC.
Key Statistics (as of June 10, 2026 at 00:28 UTC)
| Price | USD 2.18 |
|---|---|
| Change | ▼ 0.68% (down) |
| Previous Close | USD 2.19 |
| Open | USD 2.2 |
| Day Range | USD 2.15 – 2.2 |
| 52-Week Range | USD 1.92 – 15.6 |
| Volume | 6,790 shares |
| Market Cap | $5.26M |
| Exchange | NCM |
Technical Analysis (BGLC)
Nexqual's technical model rates BGLC "NEUTRAL" based on 3 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:28 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.88 (neutral) |
| vs SMA50 | Above (USD 2.16) |
| MACD | 0.03 (positive) |
Analyst Ratings (BGLC)
Wall Street analysts rate BGLC "None", per Nexqual as of June 10, 2026 at 00:28 UTC.
| Consensus Rating | None |
|---|
Earnings (BGLC)
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financials & Fundamentals (BGLC)
| Total Revenue | $5.31M |
|---|---|
| Revenue Growth (YoY) | -98.90% |
| Gross Margin | +13.95% |
| Operating Margin | -2466.01% |
| Profit Margin | -54.70% |
| ROE | -36.62% |
| Debt / Equity | 4.28 |
| Current Ratio | 6.52 |
| Total Cash | $3.96M |
| Total Debt | $346,624 |
| Free Cash Flow | $-170,052 |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Financial Health Score (BGLC)
Nexqual rates Bionexus Gene Lab Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:28 UTC.
| Growth | Critical — Revenue -99% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$170K, burning cash |
| Efficiency | Critical — ROE -37%, ROA -20.8% |
Ownership (BGLC)
| Insider Ownership | +35.59% |
|---|---|
| Institutional Ownership | +0.01% |
| Shares Outstanding | 2.42M |
| Float | 1.76M |
| Short % of Float | +0.52% |
Source: Nexqual, June 10, 2026 at 00:28 UTC.
Leadership (BGLC)
Bionexus Gene Lab Corp is led by Su-Leng Tan (age 41), CEO, President, Secretary & Director, per Nexqual as of June 10, 2026 at 00:28 UTC.
| CEO, President, Secretary & Director | Su-Leng Tan (age 41) |
|---|---|
| Chief Financial Officer | Set Fui Chong (age 62) |
| Managing Director | Too Kam Tham |
From Bionexus Gene Lab Corp's Latest SEC 10-K Filing (filed 2026-04-14)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary algorithm software then analyzes this collected data and processes checked by the laboratory manager to ensure all the steps are followed in the deriving predictive model for each disease condition.
- By identifying disease-specific gene activity patterns, we can develop screening tools that enable early detection, monitor disease progression, and support precision interventions.   We take advantage of profiling these changes, which enables us to identify unique molecular signatures (biomarkers) reflecting disease activity which can then be used to develop disease-specific molecular diagnostic assays.
Partnerships
- MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management.   In November 2025, the Company entered into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte.
- The Company continues to evaluate MRNA Scientific's operations, commercial opportunities, and strategic direction.   In November 2025, the Company completed a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARBB | ARB IOT Group Limited | USD 5.67 | ▲ 0.98% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.17 | ▼ 12.55% |
| OMH | Ohmyhome Limited | USD 0.61 | ▼ 12.7% |
| MGIH | Millennium Group International | USD 1.69 | ▲ 19.86% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:28 UTC. This page is informational and not investment advice.